An open letter signed by more than 50 industry executives blasts a “fundamentally, fatally flawed” report that urges greater ...

A group of 53 biotech leaders are expressing their support for mifepristone in a letter to the Food and Drug Administration, ...

FDA Commissioner Marty Makary’s pledge to reexamine the safety of medication abortion isn’t just pointless — it’s dangerous.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent HIV, the creator of the drug, Gilead Sciences, announced on Wednesday.

Yeztugo (lenacapavir) is now the first and only HIV prevention option approved by the U.S. FDA that offers protection for six months. Yeztugo received FDA approval under Priority Review.

In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise ...

FDA Approves Powerful Twice-Yearly Treatment to Prevent HIV Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections By Joseph Walker and ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012 as a treatment for people with HIV that no longer responded to ...

The Food and Drug Administration has approved the world's only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday.

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and possibly eradicate the disease.

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s ...